India's Cipla misses second-quarter profit view on muted US sales

Impact · against what's priced in

Cipla faces downward pressure following a second-quarter profit miss driven by poor US performance. The combination of muted generic Revlimid sales and intense competition suggests a deterioration in margins and EPS growth projections.

CIPLA−0.50: No priced-in read yet
In context: The profit miss and specifically the muted sales of generic Revlimid indicate that US competition is weighing more heavily on the bottom line than previously estimated.
Read from the article alone

India's Cipla misses second-quarter profit view on muted US sales

healthcare
CIPLA
earnings miss
generics
india
pharma
us market

Search tags

India's Cipla misses second-quarter profit view on muted US sales

What matters in this story

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

India's Cipla misses second-quarter profit view on muted US sales

What matters in this story

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

How each ticker is affected

Track these names every morning.

BBNX Investor Class Action Filed: Beta Bionics Investors Are Alerted to the Upcoming November 3 Deadline in the Securities Fraud Class Action to Recover Losses

ENSG Investor Class Action Filed: Ensign Group Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses

ALHC Investor Investigation: Alignment Healthcare Investors Are Alerted to the Securities Fraud Investigation after Inflated EBITDA Leads to 16% Stock Drop

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

India's Cipla misses second-quarter profit view on muted US sales

What matters in this story

Next reads from the same story arc

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

India's Cipla misses second-quarter profit view on muted US sales

What matters in this story

Next reads from the same story arc

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

How each ticker is affected

Track these names every morning.

BBNX Investor Class Action Filed: Beta Bionics Investors Are Alerted to the Upcoming November 3 Deadline in the Securities Fraud Class Action to Recover Losses

ENSG Investor Class Action Filed: Ensign Group Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses

ALHC Investor Investigation: Alignment Healthcare Investors Are Alerted to the Securities Fraud Investigation after Inflated EBITDA Leads to 16% Stock Drop

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript